Preliminary one-year data from the Xplore-1 clinical trial, evaluating Xeltis’ restorative pulmonary heart, valve will be presented for the first time at the ECHSA meeting in Cascais, Portugal.
Trial investigator Professor Tomasz Mroczek from the Children’s University Hospital, Krakow, Poland, will illustrate one-year data from three patients he implanted with Xeltis’ restorative valve. The presentation will take place at 8:30am on June 1, Grande Real Villa Italia Hotel, Cascais, Portugal.
Xplore-1 is the first clinical trial evaluating Xeltis’ restorative heart valves. A number of academic research teams in Europe and in the United States are investigating the fundamental science behind Endogenous Tissue Restoration in heart valve therapy. Xeltis’ restorative pulmonary valve is the first of its kind to reach clinical trial stage.
A second clinical trial on Xeltis’ pulmonary valve, the FDA-approved Xplore-2 study, is currently under way in six medical centers in the USA.
In a separate session at ECHSA, an overview on Xeltis’ technology and research program and its potential additional application will be presented at 13:45 on June 1 in the Principe de Saboia as part of the Industry Innovation Symposium.